Table 1.

Clinicopathologic and molecular characteristics of patients

Chemotherapy armCombination therapy arm
n (%)n (%)Pa
Clinical tumor stage
 T221 (32)19 (29)0.86
 T339 (59)42 (64)
 T46 (9)5 (8)
Nodal status
 cN029 (44)29 (44)0.96
 cN1-310 (15)11 (17)
 pN127 (41)26 (39)
Histopathology
 Invasive ductal carcinoma54 (82)52 (79)0.68
 Invasive lobular carcinoma10 (15)13 (20)
 Other2 (3)1 (2)
Pathologic tumor grade
 13 (5)8 (12)0.28
 242 (64)43 (65)
 315 (23)12 (18)
 NA6 (9)3 (5)
Estrogen receptor status
 ER negative9 (14)12 (18)0.66
 ER positive57 (86)54 (82)
TP53 mutation status
 TP53 wild type44 (67)41 (62)0.69
 TP53 mutated18 (27)21 (32)
 NA4 (6)4 (6)
PAM50 subtypes
 Luminal-A28 (42)27 (41)0.71
 Luminal-B22 (33)18 (27)
 HER2-enriched3 (5)6 (9)
 Basal-like10 (15)11 (17)
 Normal-like2 (3)4 (6)
 NA1 (2)
  • aPearson's χ2 test, Fisher's exact test for 2 × 2 table.